Skip to main content

QNTM · Quantum Biopharma Ltd. · Metrics

Track QNTM — free
$1.42 -0.10 (-6.58%) At close · Nov 19
Market Cap
$9.13M
Shares
6.43M
Volume · Nov 19 78.98K Avg daily vol (3M) 149.43K

QNTM metrics

47 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.42
Market cap
$9.13M

Price action

23 metrics
Price change (1W)
-20.2%
Price change (30D)
-40.8%
Price change (3M)
-58.7%
Price change (6M)
-81.8%
Price change (YTD)
-80.5%
Price change (1Y)
-77.5%
Trailing year
Price change (5Y)
—
52-week high
$11.41
52-week low
$1.42
Change from 52-week high
-87.6%
Change from 52-week low
+0.0%
Annualized volatility
142.2%
Annualized volatility (3M)
76.6%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.7
RSI (14D)
24.3
Price vs SMA 50
-48.3%
Price vs SMA 200
-60.8%
Avg volume (3M)
149,425
Relative volume
0.5
Average dollar volume
$455,859

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
6.43M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 129.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$11.19M
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$956,711.50

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-99.2%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.7
Interest coverage
-190.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$3.56M
Total assets
$17.33M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.56M
Capital expenditures (TTM)
—
R&D (TTM)
$1.48M
SG&A (TTM)
—
Stock compensation (TTM)
$2.34M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
28
13F filer change QoQ
+2
Institutional ownership
8.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+32.2%
Holder tenure
7.7
Price vs estimated holder cost
-37.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
6.8%
Latest settlement · 4.5 days to cover
Days to cover
4.5d
Short-squeeze score
54 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1771885 CUSIP 74764Y205 13F (30d) 28 filings 26 filers Visit website Investor relations